Page 11234..1020..»

Category Archives: Ulcerative Colitis

Updated Guidance on Ulcerative Colitis Management – Physician’s Weekly

Posted: January 14, 2020 at 9:48 pm

With changes in available medications and treatment paradigms, and a need to provide guidance on definitions of disease severity, the American College of Gastroenterology recently updated clinical guidance on the management of adults with ulcerative colitis (UC). Published in The American Journal of Gastroenterology, the update covers nearly a decade and includes changes in monitoring treatment response and recommendations covering all areas of UC management, such as outpatient dysplasia surveillance. Millie D. Continue reading

Posted in Ulcerative Colitis | Comments Off on Updated Guidance on Ulcerative Colitis Management – Physician’s Weekly

Gut Inflammation Linked to the Development of Parkinson Disease – Psychiatry Advisor

Posted: at 9:48 pm

A Danish study of patients with inflammatory bowel disease (IBD) and Parkinson disease (PD) found that patients with IBD had a 22% increased risk of developing PD over patients without IBD. The study, published in Gut, examined all Danish residents aged 15 years or older from 1977 to 2014 in the largest and longest population-based study of links between enteric inflammation and PD.1 A growing body of research points to the role of the gut-brain axis in the development of PD, with inflammation, irritable bowel syndrome, leaky gut, and altered gut microbiota observed in the gut, often years before the onset of symptoms of PD.2 The disease is strongly associated with the accumulation of Lewy bodies, which are eosinophilic deposits that occur within cell cytoplasm and are composed of a misfolded protein, alpha-synuclein. Some research points to the gut as the origin of the misfolded protein, spreading via the vagus nerve into the brain.3 In one study, alpha-synuclein injected in the gut walls of rats migrated to the brain stem through the vagus nerve at a rate estimated to be from 5 to 10 mm per day, thus providing startling evidence of the gut-brain connection.4 In fact, Lewy pathology can be detected in the gut of patients with PD as many as 20 years before their diagnosis via motor symptoms.5 Moreover, increases in intestinal alpha-synuclein are also strongly correlated with changes in gut microbiota that lead to inflammation and elevated permeability of the gut barrier.6 The possibility that PD may originate in the gut is also supported by discoveries of close associations between PD and inflammatory markers, including tumor necrosis factor-alpha and interleukin 6, which are present in patients with ulcerative colitis, IBD, and Crohn disease.2 Patients with PD have a distinctive fecal microbiome, even when they have shared the same diet for decades with other members of their households without PD Continue reading

Posted in Ulcerative Colitis | Comments Off on Gut Inflammation Linked to the Development of Parkinson Disease – Psychiatry Advisor

Will Theravance Biopharma Finally Break Out in 2020? – The Motley Fool

Posted: at 9:48 pm

Drug developer Theravance Biopharma (NASDAQ:TBPH) is not your typical biotech company. It emerged in 2014 from a spinoff of the R&D branch of its parent company, now called Innoviva (NASDAQ:INVA). Shareholders in Innoviva received a dividend of Theravance Biopharma stock Continue reading

Posted in Ulcerative Colitis | Comments Off on Will Theravance Biopharma Finally Break Out in 2020? – The Motley Fool

AbbVie And Allergan Merger, And Other News: The Good, Bad And Ugly Of Biopharma – Seeking Alpha

Posted: at 9:48 pm

AbbVie (ABBV) reported that it has received conditional approval in Europe for its proposed merger with Allergan (NYSE:AGN). Continue reading

Posted in Ulcerative Colitis | Comments Off on AbbVie And Allergan Merger, And Other News: The Good, Bad And Ugly Of Biopharma – Seeking Alpha

OSE Immunotherapeutics Announces Issuance of a New Patent in Japan for Tedopi on Inducing Early T-Lymphocyte Memory Response – Yahoo Finance

Posted: at 9:48 pm

Further Strengthens Global Intellectual Property Portfolio for Tedopi in Immuno-Oncology Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnmo: OSE) (Paris:OSE) today announced that the Japanese Patent Office has issued a new patent family related to Tedopi, a combination of neoepitopes, protecting the products method for inducing early T-lymphocyte memory response for use in the treatment of cancer in HLA-A2 positive patients. This patent provides a protection until 2035. Tedopi is a combination of 10 neo-epitopes, selected and optimized from five tumor associated antigens inducing a specific immune response in positive HLA-A2 patients. Continue reading

Posted in Ulcerative Colitis | Comments Off on OSE Immunotherapeutics Announces Issuance of a New Patent in Japan for Tedopi on Inducing Early T-Lymphocyte Memory Response – Yahoo Finance

Lerner and Rowe Honor the Memory of Dana Marshall-Bernstein by Supporting the Crohn’s and Colitis Foundation’s Inaugural Courage Ball – PR Web

Posted: at 9:48 pm

Lerner and Rowe Injury Attorneys LAS VEGAS (PRWEB) January 11, 2020 Lerner and Rowe Injury Attorneys is honored to pay tribute to the memory of Dana Marshall-Bernstein by supporting the Crohn's and Colitis Foundations inaugural Courage Ball. Continue reading

Posted in Ulcerative Colitis | Comments Off on Lerner and Rowe Honor the Memory of Dana Marshall-Bernstein by Supporting the Crohn’s and Colitis Foundation’s Inaugural Courage Ball – PR Web

Kicking The Tires On Protagonist Therapeutics – Seeking Alpha

Posted: January 13, 2020 at 6:52 pm

A bureaucrat who said no to everything rarely got in trouble." - Tom Clancy, Executive Orders Today, we take a look at a small 'Tier 4' biotech concern that saw several insiders buy shares in December. The insider purchases immediately follow trial results that triggered a decent sell-off in the stock. The company has an early stage but a diverse and intriguing pipeline Continue reading

Posted in Ulcerative Colitis | Comments Off on Kicking The Tires On Protagonist Therapeutics – Seeking Alpha

Phase 1 Ulcerative Colitis Trial of Brilacidin Approved by UK Regulators – IBD News Today

Posted: January 11, 2020 at 3:47 am

The United Kingdoms Medicines and Healthcare products Regulatory Agency has approved the launch of Innovation Pharmaceuticals Phase 1 trial in healthy volunteers to investigate the safety and properties of delayed-release tablets of brilacidin for the treatment of ulcerative colitis (UC). Participant screening is expected to start in the coming weeks Continue reading

Posted in Ulcerative Colitis | Comments Off on Phase 1 Ulcerative Colitis Trial of Brilacidin Approved by UK Regulators – IBD News Today

IBD Tied to Adverse Pregnancy Outcomes – MedPage Today

Posted: at 3:47 am

Women with inflammatory bowel disease (IBD) had increased risk of adverse outcomes in pregnancy, a systematic review and meta-analysis confirmed. In an analysis of 53 studies published up to May 2019 and involving a total of 7,917 IBD pregnancies and 3,253 healthy control pregnancies, Vivian Huang, MD, of the University of Toronto, and colleagues found the following odds ratios (OR) for mothers with IBD: As shown in the study online in Alimentary Pharmacology & Therapeutics, the incidence of placenta-related diseases, however, was not elevated, with rates as follows: While there was no significant increased risk for early pregnancy loss (OR 1.63, 95% CI 0.49-5.43), almost a third of all the pregnant IBD patients had C-sections, reflecting an almost twofold increase compared with those of controls, the researchers said. The heightened risk of surgical delivery remained significant for ulcerative colitis (OR 1.80, 95% CI 1.21-2.90) but not Crohn's disease (OR 1.48, 95% CI 0.94-2.34). Continue reading

Posted in Ulcerative Colitis | Comments Off on IBD Tied to Adverse Pregnancy Outcomes – MedPage Today

Higher Risk of GI Events During Immunotherapy for Patients With IBD – Cancer Therapy Advisor

Posted: at 3:47 am

Patients with underlying irritable bowel disease (IBD) have an increased risk of developing potentially severe gastrointestinal (GI) adverse events during immune checkpoint inhibitor therapy compared with patients without IBD, according to the results of an international, multicenter, retrospective study. The findings were published in the Journal of Clinical Oncology.1 The study included 102 retrospectively identified patients with IBD who were treated with an immune checkpoint inhibitor between January 2010 and February 2019 as a well as 11,377 patients without IBD to serve as a comparator group Continue reading

Posted in Ulcerative Colitis | Comments Off on Higher Risk of GI Events During Immunotherapy for Patients With IBD – Cancer Therapy Advisor

Page 11234..1020..»